Related Experiment Videos
[Second-line Hycamtin in the treatment of lung cancer]
Yi Zhang1, Xiu-yi Zhi, Li-qiang Zhao
1Department of Thoracic Surgery, Beijing Thoracic Tumor Hospital, Beijing 101149, China.
Objective:
To discuss the therapeutic effect and toxicity of second line Hycamtin for lung cancer patients.
Methods:
Ten of these 21 patients had been treated with operation. All these 21 patients received second line Hycamtin treatment; given at the dose of 1.2 mg/m(2) per day, four consecutive days as one cycle and 21 days as one course. A total of 1 - 4 courses were given according to the patient's tolerance. Four of these 21 patients also received combination of cisplatin.
Results:
Among the 13 un-operated patients, two patients showed CR, six showed PR, three SD and two PD, giving an effective rate of 62%. Among the 8 operated patients, seven showed SD but one developed distant metastasis. The 1-year survival rate was 88%.
Toxicity:
leukopenia I-II degree 14 (66.7%), leukopenia III-IV degree 5 (23.8%), thrombocytopenia III-IV degree 1 (4.8%) and one patient died of high fever and neutocytopenia. Nausea 8 (38.1%), vomiting 3 (14.3%) and diarrhea 2 (9.5%) alopecia 4 (19.1%). Were the other side-effects.
Conclusion:
Hycamtin is indicated for second line therapy for lung cancer giving tolerable toxicity.